ArticleScience translational medicine2021
Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.
Abstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- CXCR6+ CD127- Tr1 cells balance immunity and persistence in Plasmodium falciparum infection.The Journal of clinical investigation · 2026Article
- Epigenetic landscape, key transcriptional regulators, and in vivo identification of human Tr1 cells.Science advances · 2026Article
- Precision Immunoregulation in transplantation: The rise of engineered Treg therapies.Molecular biology reports · 2026Review
- Advances in Cell Therapy for Chronic Graft-versus-Host Disease: Prophylactic and Therapeutic Perspectives.Clinical and experimental medicine · 2026Review
- Single-cell immunophenotyping identifies CD8+GZMK+IFNG+ T cells as a key immune population in cutaneous Lyme disease.JCI insight · 2026Article
- FOXP3 Stability-Adaptation Paradox: Reshaping Treg-Based Therapies for Intestinal Diseases.International journal of biological sciences · 2026Review
- Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance.Frontiers in immunology · 2026Article
- Heterogeneity in semen-mediated tolerogenic responses: defining immunological determinants of reproductive compatibility.Human reproduction open · 2026Article
- EomesoderminImmunity · 2025Article
- CXCR6bioRxiv : the preprint server for biology · 2025Article
- Regulatory T cell therapy for Graft-versus-Host Disease.Bone marrow transplantation · 2025Review
- Leveraging current insights on IL-10-producing dendritic cells for developing effective immunotherapeutic approaches.FEBS letters · 2025Review
- Regulatory T Cell in Kidney Transplant: The Future of Cell Therapy?Antibodies (Basel, Switzerland) · 2025Review
- Regulatory T cell therapies to treat autoimmune diseases and transplant rejection.Nature immunology · 2025Article
- Interferon-γ and IL-27 positively regulate type 1 regulatory T cell development during adaptive tolerance.iScience · 2025Article
- Article
- Review
- Hematopoietic Stem Cells and Their Niche in Bone Marrow.International journal of molecular sciences · 2024Review
- CTLs heterogeneity and plasticity: implications for cancer immunotherapy.Molecular cancer · 2024Review
- IL-10-producing regulatory cells impact on celiac disease evolution.Clinical immunology (Orlando, Fla.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Pauline P ChenDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-4730-3370
Alma-Martina CepikaDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-2862-1901
Rajni Agarwal-HashmiDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-3865-8866
Gopin SainiDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-7842-1241
Molly J UyedaDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
David M LouisInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6845-5437
Brandon CieniewiczDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-3268-7444
Mansi NarulaDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Laura C Amaya HernandezInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-8742-9111
Nicholas HarreDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-5377-9105
Liwen XuDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Benjamin Craig ThomasDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xuhuai JiStanford Functional Genomics Facility, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-1768-6403
Parveen ShirazDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6721-0358
Keri M TateStanford Laboratory for Cell and Gene Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-8165-5049
Dana MargittaiStanford Laboratory for Cell and Gene Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-2992-5931
Neehar BhatiaStanford Laboratory for Cell and Gene Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-9829-1453
Everett MeyerDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-7953-853X
Alice BertainaDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-3729-436X
Mark M DavisInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6868-657X
Rosa BacchettaDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-0606-6268
Maria Grazia RoncaroloDivision of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-1636-1495
Funding
TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3MStanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5MHigh Throughput DNA Sequencer UpgradeS10OD018220 · OD · STANFORD UNIVERSITY · PI COLLER, JOHN · 2014 to 2014
$596kNCI NIH HHS P01 CA049605NIDDK NIH HHS P30 DK116074NIH HHS S10 OD018220
Abstract
Type 1 regulatory T (Tr1) cells are inducible, interleukin (IL)-10
Indexed as
IsoantigensProgrammed Cell Death 1 ReceptorCD4-Positive T-LymphocytesCTLA-4 AntigenHumansT-Lymphocytes, RegulatoryCTLA-4 AntigenIsoantigensProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.